Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Buy
52
ANVS Quote, Financials, Valuation and Earnings
Last price:
$4.57
Seasonality move
:
49.16%
Day range:
$4.40 - $4.76
52-week range:
$1.11 - $6.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
9.17x
Volume:
604K
Avg. volume:
2.8M
1-year change:
-21.82%
Market cap:
$120.6M
Revenue:
--
EPS (TTM):
-$1.48
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
ANVS
Annovis Bio, Inc.
|
-- | -$0.37 | -- | -37.21% | $13.75 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
ELMD
Electromed, Inc.
|
$16.6M | -- | 11.04% | -- | $36.00 |
|
MYO
Myomo, Inc.
|
$9.4M | -$0.11 | -13.8% | -1168.66% | $5.00 |
|
VNRX
VolitionRX Ltd.
|
$806.3K | -$0.04 | 272.5% | -33.67% | $2.60 |
|
XTNT
Xtant Medical Holdings, Inc.
|
$28.5M | -- | 2.34% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
ANVS
Annovis Bio, Inc.
|
$4.55 | $13.75 | $120.6M | -- | $0.00 | 0% | -- |
|
CATX
Perspective Therapeutics, Inc.
|
$2.4000 | $12.3077 | $178.4M | -- | $0.00 | 0% | 162.73x |
|
ELMD
Electromed, Inc.
|
$27.81 | $36.00 | $231.9M | 29.92x | $0.00 | 0% | 3.71x |
|
MYO
Myomo, Inc.
|
$1.04 | $5.00 | $40M | -- | $0.00 | 0% | 1.02x |
|
VNRX
VolitionRX Ltd.
|
$0.30 | $2.60 | $36.8M | -- | $0.00 | 0% | 20.54x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.62 | $1.50 | $86.2M | 60.39x | $0.00 | 0% | 0.67x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
ANVS
Annovis Bio, Inc.
|
-- | 3.921 | -- | 4.09x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
ELMD
Electromed, Inc.
|
-- | 1.217 | -- | 4.58x |
|
MYO
Myomo, Inc.
|
45.68% | -2.855 | 35.87% | 1.94x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
ANVS
Annovis Bio, Inc.
|
-- | -$7.4M | -173.02% | -173.02% | -- | -$3.5M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
ELMD
Electromed, Inc.
|
$13.2M | $2.7M | 18.88% | 18.89% | 15.81% | -$98K |
|
MYO
Myomo, Inc.
|
$6.4M | -$3.5M | -46.49% | -68.35% | -34.86% | -$2.9M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
Annovis Bio, Inc. vs. Competitors
-
Which has Higher Returns ANVS or CATX?
Perspective Therapeutics, Inc. has a net margin of -- compared to Annovis Bio, Inc.'s net margin of -12425.36%. Annovis Bio, Inc.'s return on equity of -173.02% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital ANVSAnnovis Bio, Inc.-- -$0.37 $13.2M CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About ANVS or CATX?
Annovis Bio, Inc. has a consensus price target of $13.75, signalling upside risk potential of 202.2%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 412.82%. Given that Perspective Therapeutics, Inc. has higher upside potential than Annovis Bio, Inc., analysts believe Perspective Therapeutics, Inc. is more attractive than Annovis Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANVSAnnovis Bio, Inc.2 0 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is ANVS or CATX More Risky?
Annovis Bio, Inc. has a beta of 1.492, which suggesting that the stock is 49.212% more volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock ANVS or CATX?
Annovis Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annovis Bio, Inc. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANVS or CATX?
Annovis Bio, Inc. quarterly revenues are --, which are smaller than Perspective Therapeutics, Inc. quarterly revenues of $209K. Annovis Bio, Inc.'s net income of -$7.3M is higher than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, Annovis Bio, Inc.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annovis Bio, Inc. is -- versus 162.73x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANVSAnnovis Bio, Inc.-- -- -- -$7.3M CATXPerspective Therapeutics, Inc.162.73x -- $209K -$26M
-
Which has Higher Returns ANVS or ELMD?
Electromed, Inc. has a net margin of -- compared to Annovis Bio, Inc.'s net margin of 12.65%. Annovis Bio, Inc.'s return on equity of -173.02% beat Electromed, Inc.'s return on equity of 18.89%.
Company Gross Margin Earnings Per Share Invested Capital ANVSAnnovis Bio, Inc.-- -$0.37 $13.2M ELMDElectromed, Inc.78.15% $0.25 $44.7M -
What do Analysts Say About ANVS or ELMD?
Annovis Bio, Inc. has a consensus price target of $13.75, signalling upside risk potential of 202.2%. On the other hand Electromed, Inc. has an analysts' consensus of $36.00 which suggests that it could grow by 29.45%. Given that Annovis Bio, Inc. has higher upside potential than Electromed, Inc., analysts believe Annovis Bio, Inc. is more attractive than Electromed, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANVSAnnovis Bio, Inc.2 0 0 ELMDElectromed, Inc.4 0 0 -
Is ANVS or ELMD More Risky?
Annovis Bio, Inc. has a beta of 1.492, which suggesting that the stock is 49.212% more volatile than S&P 500. In comparison Electromed, Inc. has a beta of 0.259, suggesting its less volatile than the S&P 500 by 74.113%.
-
Which is a Better Dividend Stock ANVS or ELMD?
Annovis Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annovis Bio, Inc. pays -- of its earnings as a dividend. Electromed, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANVS or ELMD?
Annovis Bio, Inc. quarterly revenues are --, which are smaller than Electromed, Inc. quarterly revenues of $16.9M. Annovis Bio, Inc.'s net income of -$7.3M is lower than Electromed, Inc.'s net income of $2.1M. Notably, Annovis Bio, Inc.'s price-to-earnings ratio is -- while Electromed, Inc.'s PE ratio is 29.92x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annovis Bio, Inc. is -- versus 3.71x for Electromed, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANVSAnnovis Bio, Inc.-- -- -- -$7.3M ELMDElectromed, Inc.3.71x 29.92x $16.9M $2.1M
-
Which has Higher Returns ANVS or MYO?
Myomo, Inc. has a net margin of -- compared to Annovis Bio, Inc.'s net margin of -36.3%. Annovis Bio, Inc.'s return on equity of -173.02% beat Myomo, Inc.'s return on equity of -68.35%.
Company Gross Margin Earnings Per Share Invested Capital ANVSAnnovis Bio, Inc.-- -$0.37 $13.2M MYOMyomo, Inc.63.84% -$0.09 $26.9M -
What do Analysts Say About ANVS or MYO?
Annovis Bio, Inc. has a consensus price target of $13.75, signalling upside risk potential of 202.2%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 380.77%. Given that Myomo, Inc. has higher upside potential than Annovis Bio, Inc., analysts believe Myomo, Inc. is more attractive than Annovis Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANVSAnnovis Bio, Inc.2 0 0 MYOMyomo, Inc.4 0 0 -
Is ANVS or MYO More Risky?
Annovis Bio, Inc. has a beta of 1.492, which suggesting that the stock is 49.212% more volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.
-
Which is a Better Dividend Stock ANVS or MYO?
Annovis Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annovis Bio, Inc. pays -- of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANVS or MYO?
Annovis Bio, Inc. quarterly revenues are --, which are smaller than Myomo, Inc. quarterly revenues of $10.1M. Annovis Bio, Inc.'s net income of -$7.3M is lower than Myomo, Inc.'s net income of -$3.7M. Notably, Annovis Bio, Inc.'s price-to-earnings ratio is -- while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annovis Bio, Inc. is -- versus 1.02x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANVSAnnovis Bio, Inc.-- -- -- -$7.3M MYOMyomo, Inc.1.02x -- $10.1M -$3.7M
-
Which has Higher Returns ANVS or VNRX?
VolitionRX Ltd. has a net margin of -- compared to Annovis Bio, Inc.'s net margin of -862.39%. Annovis Bio, Inc.'s return on equity of -173.02% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital ANVSAnnovis Bio, Inc.-- -$0.37 $13.2M VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About ANVS or VNRX?
Annovis Bio, Inc. has a consensus price target of $13.75, signalling upside risk potential of 202.2%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.60 which suggests that it could grow by 767.53%. Given that VolitionRX Ltd. has higher upside potential than Annovis Bio, Inc., analysts believe VolitionRX Ltd. is more attractive than Annovis Bio, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANVSAnnovis Bio, Inc.2 0 0 VNRXVolitionRX Ltd.4 2 0 -
Is ANVS or VNRX More Risky?
Annovis Bio, Inc. has a beta of 1.492, which suggesting that the stock is 49.212% more volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock ANVS or VNRX?
Annovis Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annovis Bio, Inc. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANVS or VNRX?
Annovis Bio, Inc. quarterly revenues are --, which are smaller than VolitionRX Ltd. quarterly revenues of $627.3K. Annovis Bio, Inc.'s net income of -$7.3M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, Annovis Bio, Inc.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annovis Bio, Inc. is -- versus 20.54x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANVSAnnovis Bio, Inc.-- -- -- -$7.3M VNRXVolitionRX Ltd.20.54x -- $627.3K -$5.4M
-
Which has Higher Returns ANVS or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -- compared to Annovis Bio, Inc.'s net margin of 3.93%. Annovis Bio, Inc.'s return on equity of -173.02% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital ANVSAnnovis Bio, Inc.-- -$0.37 $13.2M XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About ANVS or XTNT?
Annovis Bio, Inc. has a consensus price target of $13.75, signalling upside risk potential of 202.2%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 143.51%. Given that Annovis Bio, Inc. has higher upside potential than Xtant Medical Holdings, Inc., analysts believe Annovis Bio, Inc. is more attractive than Xtant Medical Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings ANVSAnnovis Bio, Inc.2 0 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is ANVS or XTNT More Risky?
Annovis Bio, Inc. has a beta of 1.492, which suggesting that the stock is 49.212% more volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock ANVS or XTNT?
Annovis Bio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Annovis Bio, Inc. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios ANVS or XTNT?
Annovis Bio, Inc. quarterly revenues are --, which are smaller than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. Annovis Bio, Inc.'s net income of -$7.3M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, Annovis Bio, Inc.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 60.39x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Annovis Bio, Inc. is -- versus 0.67x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income ANVSAnnovis Bio, Inc.-- -- -- -$7.3M XTNTXtant Medical Holdings, Inc.0.67x 60.39x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
